[en] Human pDCs represent a rare population of circulating
cells characterized by a rapid and massive TLR-dependent
secretion of type I IFN in response to pathogenic
agents or danger signals. Through their capacity to bring
together innate and adaptive immunity and to secrete
soluble factors controlling cancer development, these
cells could represent important actors in antitumor immunity.
However, accumulating evidence suggests that
pDCs recruited to the tumor microenvironment often display
a nonactivated state and are associated with the development
and maintenance of immunosuppression.
Here, we present an overview of neoplastic lesions associated
with an infiltration of immunosuppressive/
tolerogenic pDC. Moreover, as the proper response of
pDC against cancer depends on a critical balance between
immune-activating and immune-suppressing
mechanisms, we summarize current knowledge about
the molecular pathways developed by tumors to prevent
antitumoral pDC immune responses. A better understanding
of the mechanisms regulating pDC function
in tumors could aid in the development of new therapies.
Indeed, effective cancer vaccines or therapies
could combine immunoactivating strategies (i.e., TLR
agonists) with elimination of immune-suppressing
mechanisms, leading to pDC reprogramming and thus,
allowing tumor rejection in a clinical setting.
Disciplines :
Oncology
Author, co-author :
Demoulin, Stéphanie ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Herfs, Michael ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Hubert, Pascale ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques
Language :
English
Title :
Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms
Publication date :
2013
Journal title :
Journal of Leukocyte Biology
ISSN :
0741-5400
Publisher :
Wiley Liss, Inc., New York, United States - New York
Gilliet, M., Cao, W., Liu, Y. J. (2008) Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8, 594-606.
Sisirak, V., Vey, N., Vanbervliet, B., Duhen, T., Puisieux, I., Homey, B., Bowman, E. P., Trinchieri, G., Dubois, B., Kaiserlian, D., Lira, S. A., Puisieux, A., Blay, J. Y., Caux, C., Bendriss-Vermare, N. (2011) CCR6/ CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood 118, 5130-5140.
Reizis, B., Bunin, A., Ghosh, H. S., Lewis, K. L., Sisirak, V. (2011) Plasmacytoid dendritic cells: recent progress and open questions. Annu. Rev. Immunol. 29, 163-183.
Von Marschall, Z., Scholz, A., Cramer, T., Schafer, G., Schirner, M., Oberg, K., Wiedenmann, B., Hocker, M., Rosewicz, S. (2003) Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95, 437-448.
Oliveira, I. C., Sciavolino, P. J., Lee, T. H., Vilcek, J. (1992) Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA 89, 9049-9053.
Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., Fidler, I. J. (1995) Interferons α and β down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA 92, 4562-4566.
Shao, X., Liu, C. (2006) Influence of IFN-α and IFN-γ on lymphangiogenesis. J. Interferon Cytokine Res. 26, 568-574.
McCarty, M. F., Bielenberg, D., Donawho, C., Bucana, C. D., Fidler, I. J. (2002) Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin. Exp. Metastasis 19, 609-615.
U'Ren, L., Guth, A., Kamstock, D., Dow, S. (2010) Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol. Immunother. 59, 587-598.
Liang, S., Wei, H., Sun, R., Tian, Z. (2003) IFNα regulates NK cell cytotoxicity through STAT1 pathway. Cytokine 23, 190-199.
Marrack, P., Kappler, J., Mitchell, T. (1999) Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521-530.
Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., Mescher, M. F. (2005) Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J. Immunol. 174, 4465-4469.
Gerlini, G., Urso, C., Mariotti, G., Di Gennaro, P., Palli, D., Brandani, P., Salvadori, A., Pimpinelli, N., Reali, U. M., Borgognoni, L. (2007) Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 125, 184-193.
Hartmann, E., Wollenberg, B., Rothenfusser, S., Wagner, M., Wellisch, D., Mack, B., Giese, T., Gires, O., Endres, S., Hartmann, G. (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 63, 6478-6487.
Labidi-Galy, S. I., Sisirak, V., Meeus, P., Gobert, M., Treilleux, I., Bajard, A., Combes, J. D., Faget, J., Mithieux, F., Cassignol, A., Tredan, O., Durand, I., Menetrier-Caux, C., Caux, C., Blay, J. Y., Ray-Coquard, I., Bendriss-Vermare, N. (2011) Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 71, 5423-5434.
Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi-Galy, S. I., Goddard-Leon, S., Durand, I., Le Mercier, I., Bajard, A., Bachelot, T., Puisieux, A., Puisieux, I., Blay, J. Y., Menetrier-Caux, C., Caux, C., Bendriss-Vermare, N. (2012) Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T cell expansion and contributes to breast cancer progression. Cancer Res. 72, 5188-5197.
Faith, A., Peek, E., McDonald, J., Urry, Z., Richards, D. F., Tan, C., Santis, G., Hawrylowicz, C. (2007) Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am. J. Respir. Cell Mol. Biol. 36, 360-367.
Hofmann, M. A., Kors, C., Audring, H., Walden, P., Sterry, W., Trefzer, U. (2008) Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31, 520-527.
Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G., Gilliet, M. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 97, 1143-1153.
Drobits, B., Holcmann, M., Amberg, N., Swiecki, M., Grundtner, R., Hammer, M., Colonna, M., Sibilia, M. (2012) Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122, 575-585.
Jensen, T. O., Schmidt, H., Moller, H. J., Donskov, F., Hoyer, M., Sjoegren, P., Christensen, I. J., Steiniche, T. (2012) Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 118, 2476-2485.
Treilleux, I., Blay, J. Y., Bendriss-Vermare, N., Ray-Coquard, I., Bachelot, T., Guastalla, J. P., Bremond, A., Goddard, S., Pin, J. J., Barthelemy-Dubois, C., Lebecque, S. (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466-7474.
O'Donnell, R. K., Mick, R., Feldman, M., Hino, S., Wang, Y., Brose, M. S., Muschel, R. J. (2007) Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett. 255, 145-152.
Labidi-Galy, S. I., Treilleux, I., Goddard-Leon, S., Combes, J. D., Blay, J. Y., Ray-Coquard, I., Caux, C., Bendriss-Vermare, N. (2012) Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 1, 380-382.
Thiel, A., Kesselring, R., Pries, R., Puzik, A., Wittkopf, N., Wollenberg, B. (2011) Expression of the T cell receptor αβ on a CD123+ BDCA2+ HLA-DR+ subpopulation in head and neck squamous cell carcinoma. PLoS One 6, e15997.
Bekeredjian-Ding, I., Schafer, M., Hartmann, E., Pries, R., Parcina, M., Schneider, P., Giese, T., Endres, S., Wollenberg, B., Hartmann, G. (2009) Tumour-derived prostaglandin E and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α. Immunology 128, 439-450.
Perrot, I., Blanchard, D., Freymond, N., Isaac, S., Guibert, B., Pacheco, Y., Lebecque, S. (2007) Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J. Immunol. 178, 2763-2769.
Sorrentino, R., Morello, S., Luciano, A., Crother, T. R., Maiolino, P., Bonavita, E., Arra, C., Adcock, I. M., Arditi, M., Pinto, A. (2010) Plasmacytoid dendritic cells alter the antitumor activity of CpG-oligodeoxynucleotides in a mouse model of lung carcinoma. J. Immunol. 185, 4641-4650.
Wertel, I., Polak, G., Bednarek, W., Barczynski, B., Rolinski, J., Kotarski, J. (2008) Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin. Cytom. 74, 251-258.
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., Pustilnik, T., Curiel, D. T., Galanaud, P., Capron, F., Emilie, D., Curiel, T. J. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339-1346.
Bontkes, H. J., Ruizendaal, J. J., Kramer, D., Meijer, C. J., Hooijberg, E. (2005) Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol. Oncol. 96, 897-901.
Battaglia, A., Buzzonetti, A., Baranello, C., Ferrandina, G., Martinelli, E., Fanfani, F., Scambia, G., Fattorossi, A. (2009) Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol. Immunother. 58, 1363-1373.
Watkins, S. K., Zhu, Z., Riboldi, E., Shafer-Weaver, K. A., Stagliano, K. E., Sklavos, M. M., Ambs, S., Yagita, H., Hurwitz, A. A. (2011) FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121, 1361-1372.
Vermi, W., Bonecchi, R., Facchetti, F., Bianchi, D., Sozzani, S., Festa, S., Berenzi, A., Cella, M., Colonna, M. (2003) Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J. Pathol. 200, 255-268.
Salio, M., Cella, M., Vermi, W., Facchetti, F., Palmowski, M. J., Smith, C. L., Shepherd, D., Colonna, M., Cerundolo, V. (2003) Plasmacytoid dendritic cells prime IFN-γ-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur. J. Immunol. 33, 1052-1062.
Wenzel, J., Bekisch, B., Uerlich, M., Haller, O., Bieber, T., Tuting, T. (2005) Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions. Am. J. Clin. Pathol. 124, 37-48.
Brimnes, M. K., Svane, I. M., Johnsen, H. E. (2006) Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin. Exp. Immunol. 144, 76-84.
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., Baccarani, M., Lemoli, R. M. (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100, 230-237.
Chauhan, D., Singh, A. V., Brahmandam, M., Carrasco, R., Bandi, M., Hideshima, T., Bianchi, G., Podar, K., Tai, Y. T., Mitsiades, C., Raje, N., Jaye, D. L., Kumar, S. K., Richardson, P., Munshi, N., Anderson, K. C. (2009) Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 16, 309-323.
Hishizawa, M., Imada, K., Kitawaki, T., Ueda, M., Kadowaki, N., Uchiyama, T. (2004) Depletion and impaired interferon-α-producing capacity of blood plasmacytoid dendritic cells in human T-cell leukaemia virus type I-infected individuals. Br. J. Haematol. 125, 568-575.
Fabricius, D., Neubauer, M., Mandel, B., Schutz, C., Viardot, A., Vollmer, A., Jahrsdorfer, B., Debatin, K. M. (2010) Prostaglandin E2 inhibits IFN-α secretion and Th1 costimulation by human plasmacytoid dendritic cells via E-prostanoid 2 and E-prostanoid 4 receptor engagement. J. Immunol. 184, 677-684.
Thiel, A., Pries, R., Jeske, S., Trenkle, T., Wollenberg, B. (2009) Effect of head and neck cancer supernatant and CpG-oligonucleotides on migration and IFN-α production of plasmacytoid dendritic cells. Anticancer Res. 29, 3019-3025.
Brew, R., Erikson, J. S., West, D. C., Kinsella, A. R., Slavin, J., Christmas, S. E. (2000) Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12, 78-85.
Kamohara, H., Takahashi, M., Ishiko, T., Ogawa, M., Baba, H. (2007) Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-α and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor. Int. J. Oncol. 31, 627-632.
Ara, T., Song, L., Shimada, H., Keshelava, N., Russell, H. V., Metelitsa, L. S., Groshen, S. G., Seeger, R. C., DeClerck, Y. A. (2009) Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res. 69, 329-337.
Yao, C., Lin, Y., Chua, M. S., Ye, C. S., Bi, J., Li, W., Zhu, Y. F., Wang, S. M. (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int. J. Cancer 121, 1949-1957.
Araki, S., Omori, Y., Lyn, D., Singh, R. K., Meinbach, D. M., Sandman, Y., Lokeshwar, V. B., Lokeshwar, B. L. (2007) Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67, 6854-6862.
Brat, D. J., Bellail, A. C., Van Meir, E. G. (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7, 122-133.
Li, A., Dubey, S., Varney, M. L., Dave, B. J., Singh, R. K. (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170, 3369-3376.
Fan, Y., Ye, J., Shen, F., Zhu, Y., Yeghiazarians, Y., Zhu, W., Chen, Y., Lawton, M. T., Young, W. L., Yang, G. Y. (2008) Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow Metab. 28, 90-98.
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., Lackner, A., Carmeliet, P., Zou, W. (2004) Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64, 5535-5538.
Beckebaum, S., Zhang, X., Chen, X., Yu, Z., Frilling, A., Dworacki, G., Grosse-Wilde, H., Broelsch, C. E., Gerken, G., Cicinnati, V. R. (2004) Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 10, 7260-7269.
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., Zou, W. (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65, 5020-5026.
Fabricius, D., O'Dorisio, M. S., Blackwell, S., Jahrsdorfer, B. (2006) Human plasmacytoid dendritic cell function: inhibition of IFN-α secretion and modulation of immune phenotype by vasoactive intestinal peptide. J. Immunol. 177, 5920-5927.
Weeraratna, A. T., Jiang, Y., Hostetter, G., Rosenblatt, K., Duray, P., Bittner, M., Trent, J. M. (2002) Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1, 279-288.
Hack, K., Reilly, L., Proby, C., Fleming, C., Leigh, I., Foerster, J. (2012) Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells. Clin. Exp. Dermatol. 37, 557-561.
Wainwright, D. A., Balyasnikova, I. V., Han, Y., Lesniak, M. S. (2011) The expression of BST2 in human and experimental mouse brain tumors. Exp. Mol. Pathol. 91, 440-446.
Cai, D., Cao, J., Li, Z., Zheng, X., Yao, Y., Li, W., Yuan, Z. (2009) Upregulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 9, 102.
Tsukamoto, N., Okada, S., Onami, Y., Sasaki, Y., Umezawa, K., Kawakami, Y. (2009) Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. Clin. Cancer Res. 15, 5733-5743.
Rissoan, M. C., Duhen, T., Bridon, J. M., Bendriss-Vermare, N., Peronne, C., de Saint Vis, B., Briere, F., Bates, E. E. (2002) Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. Blood 100, 3295-3303.
Cao, W., Rosen, D. B., Ito, T., Bover, L., Bao, M., Watanabe, G., Yao, Z., Zhang, L., Lanier, L. L., Liu, Y. J. (2006) Plasmacytoid dendritic cell-specific receptor ILT7-Fc ∈RI γ inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 203, 1399-1405.
Cao, W., Bover, L., Cho, M., Wen, X., Hanabuchi, S., Bao, M., Rosen, D. B., Wang, Y. H., Shaw, J. L., Du, Q., Li, C., Arai, N., Yao, Z., Lanier, L. L., Liu, Y. J. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J. Exp. Med. 206, 1603-1614.
Meyer-Wentrup, F., Benitez-Ribas, D., Tacken, P. J., Punt, C. J., Figdor, C. G., de Vries, I. J., Adema, G. J. (2008) Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 111, 4245-4253.
Schroeder, J. T., Chichester, K. L., Bieneman, A. P. (2008) Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-κ. J. Allergy Clin. Immunol. 121, 486-491.
Schroeder, J. T., Bieneman, A. P., Xiao, H., Chichester, K. L., Vasagar, K., Saini, S., Liu, M. C. (2005) TLR9-and Fc∈RI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J. Immunol. 175, 5724-5731.
Novak, N., Allam, J. P., Hagemann, T., Jenneck, C., Laffer, S., Valenta, R., Kochan, J., Bieber, T. (2004) Characterization of Fc∈RI-bearing CD123 blood dendritic cell antigen-2 plasmacytoid dendritic cells in atopic dermatitis. J. Allergy Clin. Immunol. 114, 364-370.
Gill, M. A., Bajwa, G., George, T. A., Dong, C. C., Dougherty, I. I., Jiang, N., Gan, V. N., Gruchalla, R. S. (2010) Counterregulation between the Fc∈RI pathway and antiviral responses in human plasmacytoid dendritic cells. J. Immunol. 184, 5999-6006.
Wu, P., Wu, J., Liu, S., Han, X., Lu, J., Shi, Y., Wang, J., Lu, L., Cao, X. (2008) TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin. Immunol. 129, 40-48.
Cao, W., Zhang, L., Rosen, D. B., Bover, L., Watanabe, G., Bao, M., Lanier, L. L., Liu, Y. J. (2007) BDCA2/Fc ∈ RI γ complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol. 5, e248.
Moons, L. M., Kusters, J. G., Bultman, E., Kuipers, E. J., van Dekken, H., Tra, W. M., Kleinjan, A., Kwekkeboom, J., van Vliet, A. H., Siersema, P. D. (2005) Barrett's oesophagus is characterized by a predominantly humoral inflammatory response. J. Pathol. 207, 269-276.
Sorrentino, R., Morello, S., Pinto, A. (2010) Role of plasmacytoid dendritic cells in lung-associated inflammation. Recent Pat. Inflamm. Allergy Drug Discov. 4, 138-143.
Riboldi, E., Daniele, R., Cassatella, M. A., Sozzani, S., Bosisio, D. (2009) Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. Immunobiology 214, 868-876.
Blasius, A. L., Cella, M., Maldonado, J., Takai, T., Colonna, M. (2006) Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 107, 2474-2476.
Fuchs, A., Cella, M., Kondo, T., Colonna, M. (2005) Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 106, 2076-2082.
Byrd, A., Hoffmann, S. C., Jarahian, M., Momburg, F., Watzl, C. (2007) Expression analysis of the ligands for the natural killer cell receptors NKp30 and NKp44. PLoS One 2, e1339.
Rovere-Querini, P., Capobianco, A., Scaffidi, P., Valentinis, B., Catalanotti, F., Giazzon, M., Dumitriu, I. E., Muller, S., Iannacone, M., Traversari, C., Bianchi, M. E., Manfredi, A. A. (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 5, 825-830.
Scaffidi, P., Misteli, T., Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195.
Gardella, S., Andrei, C., Ferrera, D., Lotti, L. V., Torrisi, M. R., Bianchi, M. E., Rubartelli, A. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995-1001.
Dumitriu, I. E., Baruah, P., Valentinis, B., Voll, R. E., Herrmann, M., Nawroth, P. P., Arnold, B., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506-7515.
Semino, C., Angelini, G., Poggi, A., Rubartelli, A. (2005) NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106, 609-616.
Dumitriu, I. E., Bianchi, M. E., Bacci, M., Manfredi, A. A., Rovere-Querini, P. (2007) The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81, 84-91.
Yang, G. L., Zhang, L. H., Bo, J. J., Huo, X. J., Chen, H. G., Cao, M., Liu, D. M., Huang, Y. R. (2012) Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J. Surg. Oncol. 106, 57-61.
Lee, H., Shin, N., Song, M., Kang, U. B., Yeom, J., Lee, C., Ahn, Y. H., Yoo, J. S., Paik, Y. K., Kim, H. (2010) Analysis of nuclear high mobility group box 1 (HMGB1)-binding proteins in colon cancer cells: clustering with proteins involved in secretion and extranuclear function. J. Proteome Res. 9, 4661-4670.
Wild, C. A., Brandau, S., Lotfi, R., Mattheis, S., Gu, X., Lang, S., Bergmann, C. (2012) HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol. 48, 409-416.
Popovic, P. J., DeMarco, R., Lotze, M. T., Winikoff, S. E., Bartlett, D. L., Krieg, A. M., Guo, Z. S., Brown, C. K., Tracey, K. J., Zeh III, H. J. (2006) High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J. Immunol. 177, 8701-8707.
Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., Jinushi, M. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13, 832-842.
Schiraldi, M., Raucci, A., Munoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., Thelen, M., Varani, L., Mellado, M., Proudfoot, A., Bianchi, M. E., Uguccioni, M. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209, 551-563.
Campana, L., Bosurgi, L., Bianchi, M. E., Manfredi, A. A., Rovere-Querini, P. (2009) Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells. J. Leukoc. Biol. 86, 609-615.
Yang, H., Lundback, P., Ottosson, L., Erlandsson-Harris, H., Venereau, E., Bianchi, M. E., Al-Abed, Y., Andersson, U., Tracey, K. J., Antoine, D. J. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18, 250-259.
Kazama, H., Ricci, J. E., Herndon, J. M., Hoppe, G., Green, D. R., Ferguson, T. A. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29, 21-32.
Carta, S., Castellani, P., Delfino, L., Tassi, S., Vene, R., Rubartelli, A. (2009) DAMPs and inflammatory processes: the role of redox in the different outcomes. J. Leukoc. Biol. 86, 549-555.
Tang, D., Kang, R., Cheh, C. W., Livesey, K. M., Liang, X., Schapiro, N. E., Benschop, R., Sparvero, L. J., Amoscato, A. A., Tracey, K. J., Zeh, H. J., Lotze, M. T. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29, 5299-5310.
Schnurr, M., Toy, T., Shin, A., Hartmann, G., Rothenfusser, S., Soellner, J., Davis, I. D., Cebon, J., Maraskovsky, E. (2004) Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood 103, 1391-1397.
Gerlini, G., Di Gennaro, P., Mariotti, G., Urso, C., Chiarugi, A., Pimpinelli, N., Borgognoni, L. (2010) Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes. J. Invest. Dermatol. 130, 898-901.
Muller, A. J., Sharma, M. D., Chandler, P. R., Duhadaway, J. B., Everhart, M. E., Johnson III, B. A., Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H., Prendergast, G. C., Mellor, A. L. (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA 105, 17073-17078.
Sharma, M. D., Baban, B., Chandler, P., Hou, D. Y., Singh, N., Yagita, H., Azuma, M., Blazar, B. R., Mellor, A. L., Munn, D. H. (2007) Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570-2582.
Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J., Bhardwaj, N. (2008) HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118, 3431-3439.
Chen, W., Liang, X., Peterson, A. J., Munn, D. H., Blazar, B. R. (2008) The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181, 5396-5404.
Ito, T., Yang, M., Wang, Y. H., Lande, R., Gregorio, J., Perng, O. A., Qin, X. F., Liu, Y. J., Gilliet, M. (2007) Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 204, 105-115.
Conrad, C., Gregorio, J., Wang, Y. H., Ito, T., Meller, S., Hanabuchi, S., Anderson, S., Atkinson, N., Ramirez, P. T., Liu, Y., Freedman, R. S., Gilliet, M. (2012) Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS co-stimulation of Foxp3+ T regulatory cells. Cancer Res. 72, 5240-5249.
Jahrsdorfer, B., Vollmer, A., Blackwell, S. E., Maier, J., Sontheimer, K., Beyer, T., Mandel, B., Lunov, O., Tron, K., Nienhaus, G. U., Simmet, T., Debatin, K. M., Weiner, G. J., Fabricius, D. (2010) Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115, 1156-1165.
Bratke, K., Nielsen, J., Manig, F., Klein, C., Kuepper, M., Geyer, S., Julius, P., Lommatzsch, M., Virchow, J. C. (2010) Functional expression of granzyme B in human plasmacytoid dendritic cells: a role in allergic inflammation. Clin. Exp. Allergy 40, 1015-1024.
Gondek, D. C., Lu, L. F., Quezada, S. A., Sakaguchi, S., Noelle, R. J. (2005) Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174, 1783-1786.
Grossman, W. J., Verbsky, J. W., Tollefsen, B. L., Kemper, C., Atkinson, J. P., Ley, T. J. (2004) Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104, 2840-2848.
Schon, M. P., Schon, M. (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27, 190-199.
Kalb, M. L., Glaser, A., Stary, G., Koszik, F., Stingl, G. (2012) TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod-and IFN-α-mediated antitumor reactivity. J. Immunol. 188, 1583-1591.
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., Stingl, G. (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J. Exp. Med. 204, 1441-1451.
Krieg, A. M. (2008) Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161-167.
Molenkamp, B. G., van Leeuwen, P. A., Meijer, S., Sluijter, B. J., Wijnands, P. G., Baars, A., van den Eertwegh, A. J., Scheper, R. J., de Gruijl, T. D. (2007) Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 13, 2961-2969.
Speiser, D. E., Lienard, D., Rufer, N., Rubio-Godoy, V., Rimoldi, D., Lejeune, F., Krieg, A. M., Cerottini, J. C., Romero, P. (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115, 739-746.
Kim, Y. H., Girardi, M., Duvic, M., Kuzel, T., Link, B. K., Pinter-Brown, L., Rook, A. H. (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 63, 975-983.
Liu, C., Lou, Y., Lizee, G., Qin, H., Liu, S., Rabinovich, B., Kim, G. J., Wang, Y. H., Ye, Y., Sikora, A. G., Overwijk, W. W., Liu, Y. J., Wang, G., Hwu, P. (2008) Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J. Clin. Invest. 118, 1165-1175.
Vicari, A. P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M. P., O'Garra, A., Trinchieri, G., Caux, C. (2002) Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541-549.
